| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/15/2005 | EP1538980A1 Devices and methodologies useful in body aesthetics |
| 06/15/2005 | EP1538908A2 Novel substituted benzimidazole dosage forms and method of using same |
| 06/15/2005 | EP1474154B1 Improvements in or relating to compositions |
| 06/15/2005 | EP1435937B1 Composition comprising paracetamol and a bitterness masking component |
| 06/15/2005 | EP1372669B1 Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof |
| 06/15/2005 | EP1311259B1 Pharmaceutical composition comprising an ester of 5-aminolevulinic acid as photochemotherapeutic agent and a mucoadhesive agent |
| 06/15/2005 | EP1299107B1 Highly concentrated stable meloxicam solutions |
| 06/15/2005 | EP1259261B1 Pharmaceutical compositions comprising terbinafine |
| 06/15/2005 | EP1251841B1 Camphor aqueous solution for treating degenerative or autoimmune diseases and as immunomodulatory agent |
| 06/15/2005 | EP1237872A4 Compounds and compositions for delivering active agents |
| 06/15/2005 | EP1229900B1 Sustained-release drug formulations for implantation |
| 06/15/2005 | EP1222217B1 Uniform molecular weight polymers |
| 06/15/2005 | EP1174124B1 preparations for the percutanous administration of hydrophilic agents |
| 06/15/2005 | EP1165070B1 Thiadiazolyl urea or thiourea derivatives for antiviral treatment |
| 06/15/2005 | EP1162955B1 Nanoparticles, complexes with polynucleotides and their use |
| 06/15/2005 | EP1075282B1 Peg-lhrh analog conjugates |
| 06/15/2005 | EP1066059B1 Formulations for protection of peg-interferon alpha conjugates |
| 06/15/2005 | EP1037647B2 Medicinal plant dry extracts |
| 06/15/2005 | EP1023047B1 Particles |
| 06/15/2005 | EP0734247B2 Cosmetic and/or pharmaceutical preparations |
| 06/15/2005 | CN1628129A Stabilization of protein preparations |
| 06/15/2005 | CN1628126A Modified transferrin fusion proteins |
| 06/15/2005 | CN1627959A Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| 06/15/2005 | CN1627958A Immunocytokine-containing lyophilized preparation |
| 06/15/2005 | CN1627956A Compositions containing oat straw and willowherb extract |
| 06/15/2005 | CN1627955A Hepatocurative effect of emblica officinalis on hepatotoxicity related to cytoch rome P-45O |
| 06/15/2005 | CN1627951A Compositions and method for prophylaxis and treatment of aphthous ulcers and herpes simplex lesions |
| 06/15/2005 | CN1627950A Stable pharmaceutical composition useful for treating gastrointestinal disorders |
| 06/15/2005 | CN1627948A Compsn. and its for treatment of inflammatory bowel diseases |
| 06/15/2005 | CN1627938A Pharmaceutical dosage form for mucosal delivery |
| 06/15/2005 | CN1627937A Oral pediatric trimethobenzamide formulations and methods |
| 06/15/2005 | CN1627935A Oral trimethobenzamide formulations and methods |
| 06/15/2005 | CN1626566A Process for the removal of porogens from temperature sensitive macroreticular polymers using steam at reduced pressure |
| 06/15/2005 | CN1626243A Sustained release ionic conjugate |
| 06/15/2005 | CN1626239A Use of TGF-beta and growth factor in treatment and prevention of intestinal mucosa diseases |
| 06/15/2005 | CN1626094A Quetiapingranulater |
| 06/15/2005 | CN1626082A Nano particles of polyglycol-poly(lactide-caprolactone) of carrying camptothecin and preparation method |
| 06/15/2005 | CN1626068A Combination of medication in use for improving dissolution of curcumin and bioavailability as well as preparation method |
| 06/15/2005 | CN1206267C Film coatings and film coating compositions based on polyvinyl alcohol |
| 06/15/2005 | CN1206257C Hydrophilic polymer-combo of silybum mariamum extract product as well as medicinal combinatio ncontaining the combo |
| 06/15/2005 | CN1206137C Injection-moulded water soluble container |
| 06/15/2005 | CN1206002C Combined polymer-medicine micelle and its prepn process |
| 06/15/2005 | CN1206001C Biodegradable carrier and biodegradable transfer system |
| 06/15/2005 | CN1205999C Liposone composition and method for administration of a radiosensitizer |
| 06/15/2005 | CN1205995C Hybrid polypeptides with enhanced pharmacokinetic properties |
| 06/15/2005 | CN1205994C Pulmonary delivery of active agents |
| 06/15/2005 | CN1205931C Pharmaeutical agent comprising benzamide derivative as active ingredient |
| 06/15/2005 | CN1205924C Method for wrapping kmedicine by liposome |
| 06/15/2005 | CN1205923C Liposome-entrapped topoisomerase inhibitors |
| 06/15/2005 | CN1205922C Preparation of aqueous clear solution dosage forms with bile acids |
| 06/15/2005 | CN1205921C Long acting injectable formulations contg. hydrogenated castor oil |
| 06/14/2005 | US6906203 Anticancer agents; such as 2-Amino-3-cyano-4-(2-bromo-4,5-dimethoxyphenyl)-4H-indolo(4,5-b)pyran |
| 06/14/2005 | US6906182 Inhibiting abnormal cellular proliferation in a mammal; and a method of inhibiting replication of a virus in a mammal. |
| 06/14/2005 | US6906106 Compositions for the skin comprising fibers and ubiquinones and methods of using the same |
| 06/14/2005 | US6906050 With various substitutents in the 12- and 17-positions of the porphyrin skeleton; atherosclerosis, restenosis |
| 06/14/2005 | US6906047 Aqueous ifosfamide composition |
| 06/14/2005 | US6906042 Micelles |
| 06/14/2005 | US6906041 Treatment of immune diseases |
| 06/14/2005 | US6906031 Polyacid glycopeptide derivatives |
| 06/14/2005 | US6906028 Stable insulin formulations |
| 06/14/2005 | US6906027 Composition for nasal administration of insulin |
| 06/14/2005 | US6905884 Fluorescent cobalamins and uses thereof |
| 06/14/2005 | US6905702 Methods for regulating blood glucose and appetite suppression in type 2 diabetics |
| 06/14/2005 | US6905700 Interpenetrating polymer network containing hydrophobic, hydrophilic polymers; sustained release; crosslinked, three-dimensional structure |
| 06/14/2005 | US6905692 Suitable for topical application to skin or mucosal membranes of a mammal, which are utilized to inhibit the growth of bacteria, yeasts, fungi, viruses |
| 06/14/2005 | US6905688 Comprises therapeutic fusion proteins for diagnosis and treatment of cancers, neovascularization and autoimmune diseases |
| 06/14/2005 | US6905687 Fusion proteins; immunogens; solid phase synthesis; kits |
| 06/14/2005 | US6905675 Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions |
| 06/14/2005 | CA2459239C Hydrogenated castor oil dispersed in a lipid for pharmaceutically elegant topical ointment |
| 06/14/2005 | CA2400318C Botulinum toxin pharmaceutical compositions |
| 06/14/2005 | CA2346567C Method for preparing a solution for nasal spray containing sex hormones and a cyclodextrin |
| 06/14/2005 | CA2327285C Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same |
| 06/14/2005 | CA2164088C Plasmids suitable for gene therapy |
| 06/09/2005 | WO2005052184A1 Use of isogenic drug-resistant cell lines to determine the sequence of chemotherapeutic drug treatment |
| 06/09/2005 | WO2005052158A1 Anticarcinoma antibidies and uses thereof |
| 06/09/2005 | WO2005052116A2 Preservative-containing virus formulations |
| 06/09/2005 | WO2005052008A1 NONREDUCING β-GLUCAN DERIVATIVE |
| 06/09/2005 | WO2005052007A1 Recombinant anti-cd64-immunotoxins |
| 06/09/2005 | WO2005052006A2 Mutated anti-cd22 antibodies and immunoconjugates |
| 06/09/2005 | WO2005051976A2 Protein and peptide ligation processes and one-step purification processes |
| 06/09/2005 | WO2005051902A2 MODIFIED MscL PROTEIN CHANNEL |
| 06/09/2005 | WO2005051870A2 Hydrazides and derivatives production process from hydrazines and dicarboxylic acids |
| 06/09/2005 | WO2005051476A1 Method and system for rapid transdermal administration |
| 06/09/2005 | WO2005051429A2 Targeted conjugates with a modified saccharide linker |
| 06/09/2005 | WO2005051428A2 Method for obtaining a thermoreversible gel with a controlled three-dimensional structure, and gel obtained |
| 06/09/2005 | WO2005051422A1 Method for the treatment of multiple sclerosis by inhibiting il-17 activity |
| 06/09/2005 | WO2005051418A2 Pharmaceutical formulations for the sustained release of interleukins and therapeutic applications thereof |
| 06/09/2005 | WO2005051417A1 Pharmaceutical formulations for the sustained release of interferons and therapeutic applications thereof |
| 06/09/2005 | WO2005051416A1 Pharmaceutical formulations for the sustained release of one or more active principles and applications thereof, such as therapeutic applications |
| 06/09/2005 | WO2005051365A1 Composition and device for facilitating venipuncture |
| 06/09/2005 | WO2005051359A1 Macromolecular drug complexes having improved stability and therapeutic use of the same |
| 06/09/2005 | WO2005051351A2 Gene delivery mediated by liposome-dna complex with cleavable peg surface modification |
| 06/09/2005 | WO2005051347A2 A simple process and formulation for making taste- masked ibuprofen liquid preparations and similar good-tasting preparation of other pharmaceutically active or bitter, poor tasting compounds for the production of liquid preparations |
| 06/09/2005 | WO2005051342A1 Antimicrobial compositions containing an aromatic carboxylic acid and a hydric solvent |
| 06/09/2005 | WO2005051305A2 Enhanced drug delivery |
| 06/09/2005 | WO2005039552A3 Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives |
| 06/09/2005 | WO2005033181A3 Telechelic homopolyamino acids functionalized by hydrophobic groups and uses, particularly therapeutic, thereof |
| 06/09/2005 | WO2005025500A3 Process for preparing water soluble diterpenes and their applications |
| 06/09/2005 | WO2005023294A3 Polyacetal drug conjugates as release system |
| 06/09/2005 | WO2005023177A3 Human monoclonal antibodies against bacillusanthracis protective antigen |